27 November 2025 - The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global Phase 3 studies demonstrating Eydenzelt is similar in efficacy and safety for all approved indications.

Celltrion today announced that Health Canada has approved Eydenzelt, a biosimilar referencing Eylea (aflibercept 2 mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea.

Read Celltrion press release